Drug Trial Radar · NCT07706530
Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Clarent Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks
Conditions
- Arthritic Psoriasis
Interventions
CBP-0276 capsules 100mgDrug
capsule with CBP-0276 powder
PlaceboDrug
Capsule with placebo for CBP-0276
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change on severity of symptoms at lest 20% at week 24Time frame: week 24 after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Innovacion y Desarrollo en Ciencias de la Salud (IDeCSa)
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.